CD37 CD37 molecule
ENSG00000104894 · protein coding · Open Targets profile
Structural component of specialized membrane microdomains known as tetraspanin-enriched microdomains (TERMs), which act as platforms for receptor clustering and signaling. Participates thereby in diverse biological functions such as cell signal transduction, adhesion, migration and protein trafficking (PubMed:22624718). Upon ligand binding, two signaling pathways are activated, one acting through phosphorylation by LYN leading to cell death or a survival pathway with activation of GSK3B (PubMed:22624718). Plays an essential role essential for clustering of integrin ITGA4/ITGB1 and promotes its mobility in the plasma membrane of B-cells. In turn, participates in ITGA4/ITGB1 integrin-mediated antiapoptotic signaling through AKT (By similarity). Also plays a role in the migration of dendritic cells and neutrophils to draining lymph nodes, as well as in their integrin- mediated adhesion (By similarity). Negatively regulates IL-6 responses through direct interaction with SOCS3 thereby preventing constitutive IL-6 signaling (PubMed:26784544). Alternatively, inhibition of IL-6 signaling can also occur via interaction and stabilization of DECTIN1/CLEC7A at the cell membrane to inhibit its ability to promote the production of IL-6 (PubMed:17182550). {ECO:0000250|UniProtKB:Q61451, ECO:0000269|PubMed:17182550, ECO:0000269|PubMed:22624718, ECO:0000269|PubMed:26784544}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Antibody
- Advanced Clinical, UniProt loc high conf, UniProt SigP or TMHMM, GO CC med conf, Human Protein Atlas loc
- PROTAC
- Database Ubiquitination, Half-life Data
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e 0.951449990272522 (upper bound 1.2517000436782837). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
No named investigators on registry trials of CD37's approved or late-stage drugs in the last three years.
3 trials of drugs against CD37 were stopped early; 1 give no reason
Terminated, withdrawn and suspended interventional trials of naratuximab emtansine, BI-836826, otlertuzumab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 3 most recent of 3.
- terminated · 2021-05-20 · Aptevo Therapeutics · matched by the registry's drug synonyms“Business decision”
- terminated · 2020-11-25 · Gilead Sciences · matched by the registry's drug synonymsNo reason given
- withdrawn · 2018-01-09 · Boehringer Ingelheim · matched by the registry's drug synonyms“Company strategic decision”
Paediatric incentives and obligations for CD37's drugs
For naratuximab emtansine, BI-836826, otlertuzumab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: yes · CD37 is on the list. Membership alone neither requires nor waives a pediatric study.Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names naratuximab emtansine, bi-836826, otlertuzumabRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/15/1494 withdrawn 18 Jul 2022: Treatment of diffuse large B-cell lymphoma; EU/3/12/1083 withdrawn 6 Dec 2012: Treatment chronic lymphocytic leukaemiaRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of naratuximab emtansine, bi-836826, otlertuzumabRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of naratuximab emtansine, bi-836826, otlertuzumabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: no · No interventional study of naratuximab emtansine, bi-836826, otlertuzumab includes patients under 18Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 3 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.